Catalyst Pharma Focuses on Firdapse Launch & Label Expansion

Catalyst Pharma Focuses on Firdapse Launch & Label Expansion

Source: 
Yahoo/Zacks.com
snippet: 

In November 2018, the company’s Firdapse (amifampridine) tablets obtained FDA approval for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. The drug became the first FDA-approved treatment for LEMS and also the first approved product in Catalyst’s portfolio.